Track topics on Twitter Track topics that are important to you
The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic
The post Biotechnology firm Stoke Therapeutics raises $90m financing appeared first on Pharma Business review.
Original Article: Biotechnology firm Stoke Therapeutics raises $90m financingNEXT ARTICLE
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins. Antisense therapy involves inhibiting production of these proteins. When a gene is known to cause a specific disease and the genetic sequence ...